# US 2022/0031808 A1 · Il-2 muteins and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031808 A1
- Document ID: US20220031808A1
- Status: Published application
- Kind: A1
- Application number: 17/201,350
- Filed: 2021-03-15
- Published: 2022-02-03
- Earliest claimed: 2017-12-06
- Assignees: Pandion Operation, Inc.
- Applicants: Pandion Operation, Inc.
- Inventors: Nathan HIGGINSON-SCOTT; Joanne L. VINEY; Jyothsna VISWESWARAIAH; Erik Robert SAMPSON; Kevin Lewis OTIPOBY
- Web page: https://patentgrep.com/patent/US20220031808A1

## CPC

- A61K 38/2013: {IL-2}
- A61K 39/39533: {against materials from animals}
- A61K 47/6813: {the drug being a peptidic cytokine, e.g. an interleukin or interferon}
- C07K 14/55: IL-2
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present application provides for IL-2 muteins, compositions comprising the same, and methods of using the same.

## Claims

### Claim at position 1

1-63. (canceled)

### Claim 64

A method of increasing T regulatory cell proliferation in a subject, the method comprising administering to the subject a pharmaceutical composition comprising a peptide comprising an amino acid sequence of SEQ. ID. NO: 27.

### Claim 65 (depends on 64)

The method of claim 64, wherein the peptide further comprises a N-terminal leader peptide having the sequence of SEQ. ID. No: 7.

### Claim 66 (depends on 64)

The method of claim 64, wherein the peptide further comprises a linker peptide at the C-terminus.

### Claim 67 (depends on 66)

The method of claim 66, wherein the linker peptide comprises the sequence of (GGGGS)n, wherein n is 1, 2, 3, or 4.

### Claim 68 (depends on 64)

The method of claim 64, wherein the peptide further comprises a Fc peptide.

### Claim 69 (depends on 68)

The method of claim 68, wherein the Fc peptide comprises the sequence of SEQ ID NO: 8 or SEQ ID NO: 15.

### Claim 70 (depends on 68)

The method of claim 68, wherein the peptide further comprises a leader peptide having the sequence of SEQ. ID. No: 7 at the N-terminus of the peptide.

### Claim 71 (depends on 68)

The method of claim 68, wherein the Fc peptide is at the C-terminus of the peptide.

### Claim 72 (depends on 68)

The method of claim 68, wherein the Fc peptide is at the N-terminus of the peptide.

### Claim 73 (depends on 64)

The method of claim 64, wherein the peptide further comprises a linker peptide that links the peptide of SEQ ID NO: 27 and a Fc peptide.

### Claim 74 (depends on 73)

The method of claim 73, wherein the peptide further comprises a leader peptide having the sequence of SEQ. ID. No: 7 at the N-terminus.

### Claim 75 (depends on 73)

The method of claim 73, wherein the linker peptide is (GGGGS)n, n is 1, 2, 3, or 4.

### Claim 76 (depends on 73)

The method of claim 73, wherein the Fc peptide comprises the sequence of SEQ ID NO: 8 or SEQ ID NO: 15.

### Claim 77 (depends on 73)

The method of claim 73, wherein the Fc peptide is at the C-terminus of the peptide.

### Claim 78 (depends on 73)

The method of claim 73, wherein the Fc peptide is at the N-terminus of the peptide.

### Claim 79 (depends on 73)

The method of claim 73, wherein the peptide comprises an amino acid sequence of SEQ ID NO: 40.

### Claim 80

A method of activating T regulatory cells in a subject, the method comprising administering to the subject a pharmaceutical composition comprising a peptide comprising an amino acid sequence of SEQ. ID. NO: 27.

### Claim 81 (depends on 80)

The method of claim 80, wherein the peptide further comprises a Fc peptide.

### Claim 82 (depends on 81)

The method of claim 81, wherein the Fc peptide is at the C-terminus or the N-terminus of the peptide.

### Claim 83 (depends on 81)

The method of claim 81, wherein the peptide comprises an amino acid sequence of SEQ ID NO: 40.
